TABLE 3.
Azacitidine Versus Conventional Care in Patients with Myelodysplastic Syndrome (n=358)*
| Response, % |
|||||
|---|---|---|---|---|---|
| Therapy | No. Treated | CR | PR | Overall | Median Survival, mo |
| Azacitidine | 179 | 18 | 12 | 29 | 24.4 |
| Conventional care | 179 | 8 | 4 | 12 | 15.5 |
| Best support | 1 | 4 | 5 | 11.5 | |
| Low-dose cytarabine | 8 | 4 | 12 | 15.3 | |
| Chemotherapy (3+7) | 36 | 4 | 40 | 15.7 | |
CR indicates complete response; PR, partial response; 3+7, intravenous daunorubicin daily X3 plus continuous-infusion cytarabine daily X7.
See Fenaux 2007.217